Evidence map›Paper›PMID 35545838›Full record

ArticleThoracic cancer2022

A targeted siRNA-loaded PDL1-exosome and functional evaluation against lung cancer.

Xianbin Lin, Liangan Lin, Jingyang Wu, Wentan Jiang, Jiayun Wu, Jianshen Yang, Chun Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. siRNA and targeted delivery systems in breast cancer therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  14. Review
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xianbin LinDepartment of Thoracic Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
Liangan LinDepartment of Thoracic Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
Jingyang WuDepartment of Thoracic Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
Wentan JiangDepartment of Thoracic Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
Jiayun WuDepartment of Thoracic Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
Jianshen YangDepartment of Thoracic Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.ORCID 0000-0002-6940-9811
Chun ChenDepartment of Thoracic Surgery, Fujian Medical University Union Hospital, Key Laboratory of Cardio-Thoracic Surgery (Fujian Medical University), Fuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs an endocytic nanosicle involved in intercellular communication, an exosome can efficiently deliver drugs from one cell to another and deliver therapeutic short interfering RNA (siRNA) to target cells. This is conducive to gene therapy for cancers. In this study, an exosome was used as the siRNA-loaded substrate to prepare a targeted siRNA-loaded PD-L1 exosome and evaluate its function against lung cancer.

methodsThe optimal preparation process and binding ratio of the targeted nanovesicle/siRNA complex was determined by detecting the particle size, potential, and other physical parameters in combination with cell binding and uptake capacity of exosome complexes. The biological cell behavior of targeted exosome nanosicles was evaluated through cytotoxicity, apoptosis, and the cell uptake capacity.

resultsA targeted exosome nanovesicle capable of loading siRNA and characterized with low toxicity, high loading rate, and the ability to be used for targeted tumor cell gene therapy was constructed.

conclusionThe PD-L1 targeting exosome can be used as an efficient siRNA delivery carrier, which is an efficient and safe nanocarrier for tumor targeted gene therapy.

Indexed as

ExosomesLung NeoplasmsB7-H1 AntigenCell Line, TumorHumansRNA, Small InterferingB7-H1 AntigenRNA, Small Interferingexosomelung cancernanocarrierPD-L1siRNA

Identifiers

PMID35545838
PMCPMC9161323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.